HYBIO(SZ:300199)2022-12-06 01:36Group 1: Fundraising and Financial Performance - The company completed a non-public stock issuance on October 17, 2016, with 28,326,178 shares issued at a price of 23.30 CNY per share, raising a total of 65,999.99 million CNY, with net proceeds of 64,405.20 million CNY after expenses [1] - The sales revenue of Terlipressin reached 68,370,177.72 CNY in the first half of 2016, representing a growth of 35.08% compared to the same period last year [3] - The company achieved a revenue of 6,837.02 million CNY from Terlipressin in the first half of 2016, also reflecting a growth of 35.08% year-on-year [4] Group 2: Product Development and Market Strategy - Terlipressin is the only known drug that can improve survival rates for patients with liver cirrhosis, indicating its significant therapeutic value [3] - The company plans to enhance academic promotion and sales efforts for Terlipressin to achieve substantial sales growth [3] - The product layout includes three main segments: API exports, domestic pharmaceuticals, and medical devices, with a focus on expanding market share in the domestic market [3] Group 3: International Market Expansion - The company has obtained DMF registration for key API products in international markets, including the US, Europe, Japan, and South Korea, and is actively pursuing ANDA applications for further market access [3] - Future strategies include strengthening overseas registration efforts for peptide drugs and expanding international customer collaborations [5] - The company aims to maintain a competitive edge in the international market by leveraging its strong R&D capabilities and product variety in the peptide drug sector [5]